BeiGene Deal History & Licensing Activity
BeiGene is a large biotech headquartered in China. Over the past three years, BeiGene has been involved in 6 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
BeiGene Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BeiGene in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Trispecific PD-1/CTLA-4/VEGF-A molecule | Huahui | Bispecific Antibodies | Unknown | option | May 2026 |
| trispecific PD-1/CTLA-4/VEGF-A molecule | Huahui Biopharma | Bispecific Antibodies | Unknown | option | May 2026 |
| CD38-tinib | AbbVie | Bispecific Antibodies | Approved | option | Oct 2025 |
BeiGene Pipeline Focus
Therapeutic areas and modalities where BeiGene is most active based on deal history and clinical trial data.
Therapeutic Areas
BeiGene Strategic Signals
Key indicators of BeiGene's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
BeiGene Clinical Pipeline
BeiGene has 50 active clinical trials across 4 development phases.
1
Phase 4
20
Phase 1
27
Phase 2
2
Phase 3
See How Your Asset Matches BeiGene's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About BeiGene Licensing & Deal Activity
BeiGene is a large biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, BeiGene ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BeiGene include Solid Tumors (21 deals and trials), Hematological Malignancies (11 deals and trials), Oncology (5 deals and trials), and Mega Deals (4 deals and trials). In terms of modality, BeiGene has shown particular interest in bispecific antibodies, small molecules, protacs.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BeiGene and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against BeiGene's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.